From AI-powered commercialization tools to wearable neurotherapies and cancer screening platforms, this week’s funding activity reflects growing investor focus on scalable, clinically validated technologies. Details follow below.
Medtronic leads $100M financing for Pulnovo Medical
Medtronic was joined by existing investors EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed and Lilly Asia Ventures. New investors, including HSG, among other prominent entities, also participated.
Funds add to a $100M Series C round last year. Separate from the financing, the companies entered into a commercial agreement that contemplates potential future commercialization opportunities.
Chair and President Cynthia Chen
Last week’s tracker: Alamar, Onward & more
AcuityMD raises $80M for AI-based commercialization platform
The Series C adds to a $45M Series B round and a $31M Series A. It brings the company’s funding to more than $160M to date. The company touts a valuation of $955M.
Existing investor StepStone Group led the financing with additional participation from Benchmark, Redpoint Ventures, ICONIQ and Atreides Management.
Founder and CEO Mike Monovoukas
Cala Health secures $50M investment for tremor management wearable
The company received a growth capital commitment from Trinity Capital, setting the company up with funds to expand its neuromodulation therapy.
Proceeds will help scale adoption of its personalized, at-home therapy designed to reduce hand tremors and improve daily function.
CEO Deanna Harshbarger
ScreenPoint Medical raises $16M with continued investment from Siemens Healthineers
The company raised $16M to advance the global expansion of its AI screening tool for breast cancer detection, with ongoing participation from Siemens Healthineers.
Aside from Siemens Healthineers, $14M of the Netherlands-based company’s funding originated from VC firm Insight Partners and other existing investors, while $2M of the tranche came from non-dilutive research grants.
CEO Pieter Kroese
Alesi Surgical raises £7M to clear the air in operating theatres
The round was led by IW Capital and supported by existing shareholders, IP Group and Mercia Ventures to tackle the problem of surgical smoke in operating theatres.
The funding will support international commercial expansion and further development of Alesi’s Ultravision2 platform as regulations around smoke control tighten.
Founder and CEO Dominic Griffiths
CheeChips completed its angel financing round
Nearly half of the funds in this round will be invested in technology R & D, including AI model iteration, new product prototype refinement, and patent layout.
30% will be used to recruit top – tier talents and expand the R & D and operation teams. The remaining 25% will be invested in market research, brand building, and user demand exploration.
Founder Li Zhigang
